SCHEDULE 13G/A: Paradigm BioCapital Entities Disclose Significant Passive Stake in Olema Pharmaceuticals

Paradigm BioCapital Advisors LP and its affiliates have filed an amended Schedule 13G, reporting a collective beneficial ownership of 9.99% in Olema Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 4 to Schedule 13G for Olema Pharmaceuticals, Inc., detailing beneficial ownership of its Common Stock.
• The Reporting Persons include Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd.
• As of December 31, 2024, Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each beneficially own 7,429,355 shares, representing 9.99% of Olema Pharmaceuticals' Common Stock.
• Paradigm BioCapital International Fund Ltd. beneficially owns 6,777,072 shares, representing 9.1% of the class.
• The reported beneficial ownership includes 6,294,992 shares of Common Stock held by the Fund and 1,009,978 shares held by separately managed accounts.
• The ownership also includes warrants exercisable within 60 days to purchase 482,080 shares held by the Fund and 124,385 shares held by the Fund and/or the Account for other Reporting Persons.
• The percentages of beneficial ownership are calculated based on 74,243,540 shares of Common Stock outstanding as of December 13, 2024, as reported by Olema Pharmaceuticals, Inc. in its Prospectus filed on January 15, 2025.
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine beneficial ownership filing (Schedule 13G Amendment), which typically does not convey positive or negative sentiment regarding the issuer's performance or outlook, but rather reports a passive investment stake.

Positives

• Disclosure of a significant passive investment stake by institutional investors (Paradigm BioCapital entities) in Olema Pharmaceuticals, which can be interpreted as a vote of confidence in the company's long-term prospects.
• The investment includes both common stock and warrants, indicating a structured approach to their position.

Risks

• The document itself does not detail specific business or financial risks of Olema Pharmaceuticals.
• The Reporting Persons disclaim beneficial ownership of any Common Stock other than what they directly own, which is a standard legal clarification rather than a business risk to the issuer.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This document is a routine beneficial ownership filing by an investment firm and does not provide specific industry context or analysis of broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional holdings, which can offer insights into investor confidence and market liquidity.

Key Dates

Keywords

Olema Pharmaceuticals, Schedule 13G, Beneficial Ownership, Paradigm BioCapital, Common Stock, Institutional Investor, SEC Filing